A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Deucravacitinib (Primary) ; Apremilast
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms POETYK-PSO-2
- Sponsors Bristol-Myers Squibb
- 16 Jan 2024 Results from NCT04036435, NCT03611751 and NCT03624127, evaluating deucravacitinib safety and efficacy over 2 years in patients, published in the British Journal of Dermatology
- 18 Dec 2023 Results from POETYK PSO-1 and PSO-2 evaluating the efficacy and safety of deucravacitinib in scalp psoriasis , published in the Journal of the American Academy of Dermatology
- 15 Nov 2023 Results of pooled analysis from POETYK PSO-1 and PSO-2 trials assessing efficacy of Deucravacitinib, presented at the ACR Convergence 2023